Nevertheless, in this therapeutic setting, clinical studies regarding the KRAS oncogene status and treatment outcomes in locally advanced rectal cancer are scarce.13 For this reason, we focused on the potential of KRAS oncogene status as a biological predictive marker for rectal cancer when 5-FU-based neoadjuvant CRT is conducted in locally advanced rectal cancer. This evidence concerns the gene KRAS and rectal cancer.